ADARx Pharmaceuticals, Inc. (ADRX)
Snapshot
- 1 week
- +7.3%+4.7% vs SPY
- 1 month
- -19.8%-16.7% vs SPY
- Market cap
- $1.5B
- P/E
- negindustry 14.9
- P/B
- 2.7
- EV/EBITDA
- -9.1
- FCF yield
- -6.2%
- Days to cover
- 5.0
- Short change
- -5.4%
- Price target
- $35.00+146.5% upside
Signal evidence
Peers
| Symbol | Name | Price | Day | Mkt cap | Call | Regime |
|---|---|---|---|---|---|---|
| STOK | Stoke Therapeutics, Inc. | $27.76 | +1.8% | $1.8B | Locked | Locked |
| SLN | Silence Therapeutics plc | $19.77 | +0.2% | $933.8M | Locked | Locked |
| MGTX | MeiraGTx Holdings plc | $9.68 | +4.4% | $929.7M | Locked | Locked |
| PRME | Prime Medicine, Inc. | $4.30 | +9.8% | $779.9M | Locked | Locked |
| WVE | Wave Life Sciences Ltd. | $3.42 | -0.9% | $674.5M | Locked | Locked |
Prediction markets
… linked markets on Kalshi and Polymarket.
Company
Healthcare · Biotechnology · CEO Zhen Li
ADARx Pharmaceuticals, Inc. (ADRX). ADARx Pharmaceuticals, Inc. operates as a clinical-stage biotechnology company that focuses on developing siRNA therapeutics to treat a broad spectrum of diseases. The company offers hepatic-targeted programs, including Agazisiran, a complement factor B (CFB) program that represents a pipeline-in-a-product opportunity, where a single therapeutic candidate has the potential to address multiple indications; Onvuzosiran, a clinical program for the prevention of HAE attacks; a…
- Zhen LiCo-Founder, President, CEO & DirectorUSD 875K
- Robert A. MacLeodChief Scientific OfficerUSD 641K
Snapshot
Price & returns1 month -19.8%
- 1 week
- +7.3%+4.7% vs SPY
- 1 month
- -19.8%-16.7% vs SPY
ValuationP/E neg vs industry 14.9 · market cap $1.5B
- Market cap
- $1.5B
- P/E
- negindustry 14.9
- P/B
- 2.7
- EV/EBITDA
- -9.1
- FCF yield
- -6.2%
Short interest & optionsDays to cover 5.0 · Short change -5.4%
- Days to cover
- 5.0
- Short change
- -5.4%
Street & earningsTarget $35.00 (+146.5% upside)
- Price target
- $35.00+146.5% upside
Signal evidence
Peers
| Symbol | Name | Price | Day | Mkt cap | Call | Regime |
|---|---|---|---|---|---|---|
| STOK | Stoke Therapeutics, Inc. | $27.76 | +1.8% | $1.8B | Locked | Locked |
| SLN | Silence Therapeutics plc | $19.77 | +0.2% | $933.8M | Locked | Locked |
| MGTX | MeiraGTx Holdings plc | $9.68 | +4.4% | $929.7M | Locked | Locked |
| PRME | Prime Medicine, Inc. | $4.30 | +9.8% | $779.9M | Locked | Locked |
| WVE | Wave Life Sciences Ltd. | $3.42 | -0.9% | $674.5M | Locked | Locked |
Prediction markets
… linked markets on Kalshi and Polymarket.
Company
Healthcare · Biotechnology · CEO Zhen Li
ADARx Pharmaceuticals, Inc. (ADRX). ADARx Pharmaceuticals, Inc. operates as a clinical-stage biotechnology company that focuses on developing siRNA therapeutics to treat a broad spectrum of diseases. The company offers hepatic-targeted programs, including Agazisiran, a complement factor B (CFB) program that represents a pipeline-in-a-product opportunity, where a single therapeutic candidate has the potential to address multiple indications; Onvuzosiran, a clinical program for the prevention of HAE attacks; a…
- Zhen LiCo-Founder, President, CEO & DirectorUSD 875K
- Robert A. MacLeodChief Scientific OfficerUSD 641K
